LL-37
LL-37 is the active 37-amino-acid piece of the only known human cathelicidin, a natural germ-fighting protein made by white blood cells, skin cells and other tissue linings. It is studied in antimicrobial and innate-immunity research.
At a glance
- Peptide
- subcutaneous
- Not yet audited here; the reference library calls it emerging
- 100 mcg per Commonly published practitioner dosing range - provider confirmation required.. All 2 sources
How much to draw
Full calculator →Opened on 100 mcg, the figure Commonly published practitioner dosing range - provider confirmation required. reports for LL-37. A reported amount, not a recommendation. Change any number to match the vial in your hand. How to reconstitute a vial.
What sources report
These are figures published elsewhere, reproduced with their source. Peppersite does not recommend an amount for LL-37 or for anything else, and nothing below has been checked against the study it came from.
| Amount | Frequency | Route | Reported by |
|---|---|---|---|
| 100 mcg SC daily or every other day | daily or every other day2-4 weeks · Short cycles; reassess | subcutaneous | Commonly published practitioner dosing range - provider confirmation required. |
| 100-200 mcg daily (SC); topical per formulation | Once daily, 5 days per week (SC); as directed (topical)2-4 weeks, then 2 weeks off · Repeatable | subcutaneous or oral or topical | Peptide Protocol Wiki |
- daily or every other day2-4 weeks · Short cycles; reassess
- subcutaneous
- Commonly published practitioner dosing range - provider confirmation required.
- Once daily, 5 days per week (SC); as directed (topical)2-4 weeks, then 2 weeks off · Repeatable
- subcutaneous or oral or topical
- Peptide Protocol Wiki
- Commonly 5 mg vials · Reconstitute with bacteriostatic water
- Bacteriostatic water
We have not published an audit on LL-37. Everything below is reference material, not our own reading of the literature, treat it as a starting point for questions, not as a grade.
How it is thought to work
LL-37 carries a positive charge that pulls it onto the negatively charged outer layer of microbes, where it can break the membrane open and kill the cell, and it also calls immune cells to a site of infection or injury. Researchers link this to an amphipathic alpha-helix shape, to chemotaxis through formyl peptide receptor-like pathways including formyl peptide receptor 2, to binding of microbial molecules such as lipopolysaccharide, DNA and RNA, and to Toll-like receptor signalling, where in psoriasis research LL-37 complexed with the body's own DNA and RNA activates TLR9 and TLR7/8 and feeds inflammation. Its effects depend heavily on context: salt, pH, proteases and local inflammation all change what it does, and a synthetic version, a peptide made at an inflamed site, and a broken-down fragment in blood may not behave the same way.
Host-defense peptide with immune-signaling activity.
Reported side effects
Seen in studies: a limited human trial tested LL-37 applied to hard-to-heal venous leg ulcers and reported wound-related outcomes and tolerability in a controlled setting. That does not amount to a full adverse-event profile.
Not ruled out: safety is incompletely characterised, especially for unapproved, compounded or research-only products. In laboratory models the concentration decides whether the effect is antimicrobial, immune-modulating, irritating or toxic to cells. There is no approved FDA label defining a safety profile for LL-37 on its own.
Sources
- ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pmc.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- jci.org
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
- clinicaltrials.gov
- pubmed.ncbi.nlm.nih.gov
- pubmed.ncbi.nlm.nih.gov
The reference sections on this page come from a compound library we import, not from our own review of the studies. Our own evidence grade appears only where an audit is linked. Research use only; nothing here is medical advice or a protocol.
KLOW is a combination of four peptides sold as one vial: GHK-Cu, KPV, BPC-157 and TB-500. It is discussed in research on tissue repair, gut, skin and recovery, though no published study has tested the four together.
KPV is a three-amino-acid peptide, lysine-proline-valine, cut from the tail end of alpha-MSH, a natural anti-inflammatory hormone. It is studied in anti-inflammatory and gut-barrier research, mostly in animal models and laboratory cell experiments.
BPC-157 (Body Protection Compound 157) is a lab-made chain of 15 amino acids based on a sequence first found in human gastric juice. It is mostly studied in animal models of tendon, ligament, gut and blood-vessel injury, and human evidence is limited to three small pilots.
GHK-Cu, or copper tripeptide-1, is a natural peptide of three amino acids bound to a copper ion, found in human blood plasma. It is studied for skin, hair and wound repair, mostly in cells and animals, with the strongest human evidence for topical use.
Glutathione (GSH) is a small molecule built from three amino acids, cysteine, glycine and glutamate, made by nearly every cell and most of all by the liver. It has been studied in people for skin lightening, liver enzymes in fatty liver disease, and Parkinson's disease.
Thymosin Alpha-1 (TA1) is a lab-made copy of a 28-amino-acid peptide that the thymus gland makes naturally. It is studied mostly in people as an immune treatment, and is approved in more than 35 countries for chronic hepatitis B, chronic hepatitis C and as an add-on in cancer care.